Collaboration Catalyzes Breakthroughs

Illumina goes beyond creating cutting-edge tools, we're a collaborative partner, connecting you with industry-leading R&D and a global network of scientific support.

Our Mission: Incept valuable partnerships with academic institutions, pharmaceutical companies and population genomics programs that enable discovery, development, and commercialization of precision medicine globally.

Your vision, amplified: How Illumina turns vision into impact

Scale and Expertise	Global presence with local connectivity
	Expertise and solutions spanning discovery through clinical translation
	Field-leading experience in regulatory strategy and commercialization
Omics Toolkit	Largest pipeline of integrated omic and informatics tools[1]
Collaborative Legacy	Demonstrated, transformative impact through collaboration[1]

More than

7,500

employees and

22,000

systems across

~165 countries

providing in-region expertise/support.

[1] https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=15da9928-16c1-453a-b908-a4469a1fc91c

illumina®

Ambitious scientific leaders across industries are shaping the next era of precision medicine. Illumina collaborations help them go further.

Two recent examples are positioned for significant advances in drug discovery and future health outcomes

Faster, more-complete drug discovery through the Alliance for Genomic Discovery (AGD)

AGD Alliance for Genomic Discovery

The AGD is an ongoing collaboration between Illumina, Nashville Biosciences, and nine leading pharmaceutical companies. The alliance has already delivered the **most comprehensive** clinical genomic dataset of its kind at **unprecedented pace**.

Through a diverse cohort with rich clinical data and AI analysis, **AGD unlocks insights often missed in homogeneous datasets**. The initiative has already identified **multiple drug candidates**, including several targets cited in Nature[2].

250,000+
genomes sequenced[3]

35,000+
individuals of diverse ancestries[3]

[2] https://www.nature.com/articles/s41467-025-57753-2

[3] https://www.prnewswire.com/news-releases/alliance-for-genomic-discovery-completes-250-000-whole-genomes-to-accelerate-drug-discovery-302405464.html

Improving real-world outcomes in Singapore: Precision Health Research Singapore (PRECISE)

PRECISE

PRECISE is a multi-year initiative advancing precision medicine in Singapore through genomics and data integration. In partnership with Illumina, the program sequenced 100,000 Singaporean genomes, making it Southeast Asia's most comprehensive population study.

Together, they've built AI-powered analysis platforms and developed local expertise and infrastructure to address ethnic disparities in genetic health.[4]

Clinically-relevant variants were identified:

1.05%
of Singaporeans carry genetic variants associated with familial hypercholesterolemia (FH)[5]

26.8%
of Singaporeans carry genetic variant linked to medication side effects[6]

1 in 150
Singaporeans have BRCA1 or BRCA2 mutations[7]

Millions
of previously unreported genomic variants were uncovered[8]

[4] https://www.npm.sg/news-and-events/press-releases/precise-illumina-partnership-agreement/

[5] https://pubmed.ncbi.nlm.nih.gov/36335097/

[6] https://www.npm.sg/empowering-seamless-access-personalised-pharmacogenomic-information-on-the-go/

[7] https://www.npm.sg/news-and-events/editorial-features/from-reactive-to-proactive-tracing-the-hereditary-cancer-risk/

[8] https://www.nature.com/articles/s41588-022-01274-x#:~:text=To%20provide%20better%20coverage%20of,.edu.sg/

Let's co-create what's next in precision medicine—your next breakthrough starts with a conversation.

Connect with us:
BusinessDevelopment@Illumina.com